170 related articles for article (PubMed ID: 32875729)
1. Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Yang X; Zhao D; Li Y; Li Y; Cui W; Li Y; Li H; Li X; Wang D
Thorac Cancer; 2020 Oct; 11(10):2858-2866. PubMed ID: 32875729
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
Yang XG; Li YY; Zhao DX; Cui W; Li H; Li XY; Li YX; Wang D
Oncol Rep; 2021 Mar; 45(3):1306-1314. PubMed ID: 33650669
[TBL] [Abstract][Full Text] [Related]
3. The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1α protein accumulation in non-small cell lung cancer cells.
Huang B; Zhou Z; Liu J; Wu X; Li X; He Q; Zhang P; Tang X
Int J Biol Sci; 2020; 16(14):2692-2703. PubMed ID: 32792865
[TBL] [Abstract][Full Text] [Related]
4. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
[TBL] [Abstract][Full Text] [Related]
5. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
6. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
7. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
Liu Y; Xia H; Wang Y; Han W; Qin J; Gao W; Qu X; Wang X
Thorac Cancer; 2021 Nov; 12(22):3053-3061. PubMed ID: 34617400
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431
[TBL] [Abstract][Full Text] [Related]
9. Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.
Niu X; Wu T; Yin Q; Gu X; Li G; Zhou C; Ma M; Su L; Tang S; Tian Y; Yang M; Cui H
Cells; 2022 Oct; 11(19):. PubMed ID: 36231056
[TBL] [Abstract][Full Text] [Related]
10. Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-κB Pathway and Its Downstream Proteins.
Chen X; Sun X; Guan J; Gai J; Xing J; Fu L; Liu S; Shen F; Chen K; Li W; Han L; Li Q
Cell Physiol Biochem; 2017; 44(6):2322-2336. PubMed ID: 29258089
[TBL] [Abstract][Full Text] [Related]
11. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
12. Blocking circ_0010235 suppresses acquired paclitaxel resistance of non-small cell lung cancer by sponging miR-512-5p to modulate FAM83F expression.
Li Y; Ma Z; Luo M; Liang R
Anticancer Drugs; 2022 Nov; 33(10):1024-1034. PubMed ID: 36206095
[TBL] [Abstract][Full Text] [Related]
13. Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
Wang L; Zhang Z; Tian H
J Clin Lab Anal; 2023 Jan; 37(1):e24781. PubMed ID: 36550019
[TBL] [Abstract][Full Text] [Related]
14. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
[TBL] [Abstract][Full Text] [Related]
16. An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.
Wang W; Wang J; Liu S; Ren Y; Wang J; Liu S; Cui W; Jia L; Tang X; Yang J; Wu C; Wang L
Mol Cancer; 2022 Apr; 21(1):106. PubMed ID: 35477569
[TBL] [Abstract][Full Text] [Related]
17. SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.
Huang Y; Wang X; Hu R; Pan G; Lin X
Oncol Rep; 2022 Oct; 48(4):. PubMed ID: 36069232
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
Gao L; Liu G; Ma J; Wang X; Wang F; Wang H; Sun J
Colloids Surf B Biointerfaces; 2014 May; 117():122-7. PubMed ID: 24632038
[TBL] [Abstract][Full Text] [Related]
19. Metformin Suppresses Stemness of Non-Small-Cell Lung Cancer Induced by Paclitaxel through FOXO3a.
Tang Z; Zhang Y; Yu Z; Luo Z
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068934
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.
Li C; Zhao X; Yang Y; Liu S; Liu Y; Li X
Med Sci Monit; 2018 May; 24():2750-2757. PubMed ID: 29723165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
